| Literature DB >> 29682581 |
Ahmed Ludvigsen Al-Mashhadi1, Christian Bo Poulsen1, Karin von Wachenfeldt2, Anna-Karin Robertson3, Jacob Fog Bentzon1, Lars Bo Nielsen4, Jesper Thygesen5, Lars Poulsen Tolbod6, Jens Rolighed Larsen7, Søren Kragh Moestrup8, Björn Frendéus3, Brynjulf Mortensen9, Ludovic Drouet10, Rozh H Al-Mashhadi1, Erling Falk1.
Abstract
BACKGROUND: Obesity and metabolic syndrome (MetS) are major risk factors for atherosclerotic diseases; however, a causal link remains elusive. Animal models resembling human MetS and its complications, while important, are scarce. We aimed at developing a porcine model of human MetS.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29682581 PMCID: PMC5845503 DOI: 10.1155/2018/6823193
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Current competing porcine models of metabolic syndrome.
| Ossabaw pig 3 | Göttingen pig 5 | Iberian pigb 4 | ||||
| Obese group | Obese group | Obese group | ||||
|
| ||||||
| Obesogenic diet | 2.0% cholesterol, 17% hydrogenated soybean oil, 2.3% corn oil, 0.7% sodium cholate | 32% crude fat, 17% protein | Ad libitum: 3.7% saturated fat, 2.8% polyunsaturated fat, 15.1% crude protein | |||
|
| ||||||
| Control diet | Lean group | Lean group | Lean group | |||
| Standard chow | Standard chow | Standard chow | ||||
| Lean ( | Obese ( | Lean ( | Obese ( | Lean ( | Obese ( | |
|
| ||||||
| Duration | 9 weeks | 5 weeks | 100 days | |||
| Weight (kg) | 29 | 45a ∗ | 21 | 27a ∗ | 209 | 251a ∗ |
| Fasting glucose (mmol/L) | <5.5 | <5.5 | 4.4 | 4.5 | <4.4 | <4.4 |
| Fasting insulin (mU/L) | <20 | <20 | 11 | 14 | <1 | <1 |
| HOMA-IR | — | — | 2.1 | 2.9 | <0.3 | <0.3 |
| Insulin AUCc (mU/L × min) | 2579 | 3811∗ | 1923 | 2895∗ | — | — |
| Glucose AUCc (mmol/L × min) | NS | NS | 578 | 636 | — | — |
| Systolic blood pressure (mmHg) | 113 | 137 | — | — | 150 | 170a |
| Diastolic blood pressure (mmHg) | 70 | 92 | — | — | 95 | 115∗ |
| Mean blood pressure (mmHg) | 79 | 107∗ | — | — | 112 | 137∗ |
| Triglycerides (mmol/L) | 0.42 | 0.57∗ | 0.13 | 0.24∗ | 0.24 | 0.32∗ |
| Cholesterol | ||||||
| Total (mmol/L) | 4.1 | 12.4∗ | 1.8 | 2.0 | 1.7 | 2.9∗ |
| HDL (mmol/L) | 1.2 | 1.0a | 0.8 | 1.0∗ a | 0.8 | 0.72a |
| LDL (mmol/L) | 2.7 | 11∗ | — | — | 1.2 | 1.6∗ |
| LDL/HDL ratio | 2.5 | 11∗ | — | — | 1.5 | 2.3∗ |
NS: data not provided but reported as nonsignificant difference. aChanges fulfill human criteria of metabolic syndrome. bAll data points read from published figures. cIVGTT in all but Iberian pig (oral GTT). 60 minutes AUC in Ossabaw pigs and 120 min AUC in Göttingen and Iberian pigs 2 g/kg orally; ∗ p < 0.05.
Study timeline. Varying metabolic assessments performed at time points W(−3) to W(30). At W(−3), we performed IVGTT on n = 7 pigs. At W18, we performed IVGTT and subcutaneous fat biopsies on all pigs. At W30, we performed IVGTT, extra- and intra-abdominal fat biopsies, and full-body computed tomography scans on all pigs.
| W(−3) | W0 | W18 | W30 | |||
|---|---|---|---|---|---|---|
| Age in weeks | 0 | 29 | 35 | 38 | 56 | 68 |
| Diet | Chow | HFFD | ||||
| Intervention | Castration | Drug trial (MLDL1278A) | CT-scans | |||
| Fasting lipids ( | Fasting lipids ( | Fasting lipids ( | ||||
| IVGTT ( | IVGTT ( | IVGTT ( | ||||
| Blood pressures | Blood pressures | |||||
| Subcutaneous AT biopsies | Subcutaneous AT biopsies | |||||
| Necropsy |
Characteristics of metabolic parameters in the FBM pigs.
| FBM pig | |||
|
| |||
| Obesogenic diet | Ad libitum: 2.0% cholesterol, 22% fat (lard), 18% fructose | ||
| Control diet | No control diet | ||
| W(−3) | W18 | W30 | |
| ( | |||
|
| |||
| Duration | 33 weeks | ||
| 12 weeks | |||
| Weight (kg) | 25.6 | 87 | 112∗ |
| Fasting glucose (mmol/L) | 3.9 (3.7–4.2) | 4.1∗ (3.9–4.3) | |
| Fasting insulin (mU/L) | 2.6 (2.2–3.2) | 3.1∗ (2.5–4.4) | |
| HOMA-IR | 0.46 (0.36–0.58) | 0.57∗ (0.43–0.86) | |
| Insulin AUC (mU/L × min) | 862 (671–1048) | 1189∗ (915–1463) | |
| Glucose AUC (mmol/L × min) | 862 (±15) | 948 (±17)∗ | |
| Systolic blood pressure (mmHg) | 141 (127–150) | 131∗ (113–141) | |
| Diastolic blood pressure (mmHg) | 68 (±13) | 66 (±14) | |
| Mean blood pressure (mmHg) | 93 (86–101) | 91 (73–97) | |
| Triglycerides (mmol/L) | 0.4 (0.4–0.5) | 0.5∗ (0.4–0.8) | |
| Cholesterol | |||
| Total (mmol/L) | 4.1 (±0.3) | 16 (±1.1)∗ | |
| HDL (mmol/L) | 0.7 (±0.1) | 2.6 (±0.3)∗ | |
| LDL (mmol/L) | 3.1 (2.4–3.8) | 14∗ (11–15) | |
| LDL/HDL ratio | 3.9 (2.8–5.7) | 5.4∗ (3.6–7.5) | |
For detailed statistical information, see supplementary information. Data is presented as mean (±SD) or median (interquartile range) where appropriate; ∗ p < 0.05.
Figure 1Body weight and fat distribution. (a) Weight gain measured throughout the study. (b) Distribution of abdominal fat depots as quantified by computed tomography scans at the level of the second lumbar vertebra. Bars represent 95% CI.
Figure 2Weight correlated with total CT cross-sectional area.
Adipose tissues and metabolic correlations.
| Model | Coefficients | Unit | Robust SE |
|
|
|---|---|---|---|---|---|
| Weight | = | ||||
|
| 0.15 kg/cm2 | 0.032 |
|
| |
|
| 0.076 kg/cm2 | 0.027 |
| ||
| c | 0.10 kg/cm2 | 0.026 |
| ||
|
| −30.9 kg | 16.3 |
| ||
|
| |||||
| CSI | = | ||||
|
| −3.10 | 1.36 |
|
| |
|
| 0.031 au | 0.0065 |
| ||
|
| |||||
| HOMA-IR | = | ||||
|
| 0.0014 au | 0.00052 |
|
| |
|
| −0.0017 au | 0.00081 |
| ||
|
| 0.55 au | 0.22 |
| ||
|
| |||||
| LDL-C | = | ||||
|
| 0.0021 mmol/(L·cm2) | 0.0054 | 0.693 | 0.16 | |
|
| −0.019 mmol/(L·cm2) | 0.0077 |
| ||
|
| 18.2 mmol/L | 1.98 | 0.000 | ||
|
| |||||
| Total cholesterol | = | ||||
|
| 0.0026 mmol/(L·cm2) | 0.0058 | 0.658 | 0.18 | |
|
| −0.024 mmol/(L·cm2) | 0.0091 |
| ||
|
| 22.58 mmol/L | 2.65 | 0.000 | ||
|
| |||||
| Mean arterial pressure | = | ||||
|
| −0.077 mmHg/cm2 | 0.036 |
| 0.12 | |
|
| 0.10 mmHg/cm2 | 0.052 | 0.057 | ||
|
| 89.0 mmHg/cm2 | 16.4 | 0.000 | ||
Figure 3HOMA-IR correlated with subcutaneous and intra-abdominal AT. XYZ plot depicting the multivariable correlation for HOMA-IR. Size of markers represents weight.
Figure 4Macrophage polarization in adipose tissues. Number of cathepsin S-positive (a) and CD163-positive (b) cells per high-power field in subcutaneous AT (assessed at time point W18 and W30), mesenteric, extraperitoneal, and perivascular AT. CD163 in perivascular AT is displayed on a separate graph due to a difference by one order of magnitude. Significance was tested with Kruskal-Wallis and corrected with Dunn's posttest for multiple comparisons. ∗ p < 0.05; ∗∗∗ p < 0.001. Bars represent median ± interquartile range.
Figure 5CD163- and CatS-positive cells in adipose tissues. (a–c) Subcutaneous (a, b) and perivascular (c) AT stained for CD163 (red) and counterstained with hematoxylin (blue). (a) Random high-power field with 0 positive cells. (b) Same section, after actively searching for an area with positive cells. (c) Perivascular AT with an average number of positive cells. (d) Crown-like structure of CatS-positive cells (brown).